JP2009524683A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009524683A5 JP2009524683A5 JP2008552474A JP2008552474A JP2009524683A5 JP 2009524683 A5 JP2009524683 A5 JP 2009524683A5 JP 2008552474 A JP2008552474 A JP 2008552474A JP 2008552474 A JP2008552474 A JP 2008552474A JP 2009524683 A5 JP2009524683 A5 JP 2009524683A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- phenyl
- methyl
- pyridin
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 67
- 125000001072 heteroaryl group Chemical group 0.000 claims 28
- 125000005843 halogen group Chemical group 0.000 claims 27
- 125000000217 alkyl group Chemical group 0.000 claims 25
- 125000001188 haloalkyl group Chemical group 0.000 claims 23
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000003107 substituted aryl group Chemical group 0.000 claims 21
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 20
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 20
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 20
- 125000003545 alkoxy group Chemical group 0.000 claims 19
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 19
- 125000004438 haloalkoxy group Chemical group 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 18
- 125000000547 substituted alkyl group Chemical group 0.000 claims 17
- 239000000651 prodrug Substances 0.000 claims 15
- 229940002612 prodrug Drugs 0.000 claims 15
- 239000012453 solvate Substances 0.000 claims 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims 14
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 14
- -1 benzoxdiazolyl Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000001786 isothiazolyl group Chemical group 0.000 claims 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 4
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000003373 pyrazinyl group Chemical group 0.000 claims 4
- BWGOFNHLWWSJNB-UHFFFAOYSA-N 3-fluoro-n-[4-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C1=NC=CS1 BWGOFNHLWWSJNB-UHFFFAOYSA-N 0.000 claims 3
- 125000002541 furyl group Chemical group 0.000 claims 3
- 125000000842 isoxazolyl group Chemical group 0.000 claims 3
- LOTBYPQQWICYBB-UHFFFAOYSA-N methyl n-hexyl-n-[2-(hexylamino)ethyl]carbamate Chemical compound CCCCCCNCCN(C(=O)OC)CCCCCC LOTBYPQQWICYBB-UHFFFAOYSA-N 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 3
- 125000000335 thiazolyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- WRHLSTUAPDFNPE-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(1,3-oxazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NC=CO1 WRHLSTUAPDFNPE-UHFFFAOYSA-N 0.000 claims 2
- FGGBQDLVIIWCEN-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NC=CS1 FGGBQDLVIIWCEN-UHFFFAOYSA-N 0.000 claims 2
- SLEWYYKLCSEZDR-UHFFFAOYSA-N 2,6-difluoro-n-[5-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]pyrimidin-2-yl]benzamide Chemical compound C1CC(C)=C(C=2C=NC(NC(=O)C=3C(=CC=CC=3F)F)=NC=2)CN1C1=NC=CS1 SLEWYYKLCSEZDR-UHFFFAOYSA-N 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- FCFQVXYTQRVKCF-UHFFFAOYSA-N [3-[4-[(2,6-difluorobenzoyl)amino]phenyl]-2-methylbut-2-enyl] acetate Chemical compound C1=CC(C(C)=C(C)COC(=O)C)=CC=C1NC(=O)C1=C(F)C=CC=C1F FCFQVXYTQRVKCF-UHFFFAOYSA-N 0.000 claims 2
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000005334 azaindolyl group Chemical group N1N=C(C2=CC=CC=C12)* 0.000 claims 2
- 125000005605 benzo group Chemical group 0.000 claims 2
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- PEZZMFSRMFVCBV-UHFFFAOYSA-N ethyl 4-methyl-5-[4-[(3-methylpyridine-4-carbonyl)amino]phenyl]-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OCC)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C PEZZMFSRMFVCBV-UHFFFAOYSA-N 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 2
- 125000005945 imidazopyridyl group Chemical group 0.000 claims 2
- 230000005931 immune cell recruitment Effects 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 230000003834 intracellular effect Effects 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- CENMJSMNRVHHGR-UHFFFAOYSA-N n-[4-(cyclohexen-1-yl)phenyl]-3-fluoropyridine-4-carboxamide Chemical compound FC1=CN=CC=C1C(=O)NC1=CC=C(C=2CCCCC=2)C=C1 CENMJSMNRVHHGR-UHFFFAOYSA-N 0.000 claims 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 2
- 125000005888 tetrahydroindolyl group Chemical group 0.000 claims 2
- 125000004306 triazinyl group Chemical group 0.000 claims 2
- PCZNZIKVYULMCE-UHFFFAOYSA-N (4-nitrophenyl) 5-[4-[(3-fluoropyridine-4-carbonyl)amino]phenyl]-4-methyl-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C(=O)OC1=CC=C([N+]([O-])=O)C=C1 PCZNZIKVYULMCE-UHFFFAOYSA-N 0.000 claims 1
- OHWRUMYXZSGSLK-UHFFFAOYSA-N 2,6-difluoro-n-[4-(2-formylcyclohepten-1-yl)phenyl]benzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2CCCCCC=2C=O)C=C1 OHWRUMYXZSGSLK-UHFFFAOYSA-N 0.000 claims 1
- NFWLUMRZUPPTIF-UHFFFAOYSA-N 2,6-difluoro-n-[4-(2-formylcyclopenten-1-yl)phenyl]benzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2CCCC=2C=O)C=C1 NFWLUMRZUPPTIF-UHFFFAOYSA-N 0.000 claims 1
- FMGXJYPTSJRXFX-UHFFFAOYSA-N 2,6-difluoro-n-[4-(2-methyl-1-phenylprop-1-enyl)phenyl]benzamide Chemical compound C=1C=C(NC(=O)C=2C(=CC=CC=2F)F)C=CC=1C(=C(C)C)C1=CC=CC=C1 FMGXJYPTSJRXFX-UHFFFAOYSA-N 0.000 claims 1
- HCCSCLWFYLZEFW-UHFFFAOYSA-N 2,6-difluoro-n-[4-(2-methylcyclohexen-1-yl)phenyl]benzamide Chemical compound C1CCCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F HCCSCLWFYLZEFW-UHFFFAOYSA-N 0.000 claims 1
- IQSDJWBNMBDLOL-UHFFFAOYSA-N 2,6-difluoro-n-[4-(4-methyl-1-pyrimidin-2-yl-3,6-dihydro-2h-pyridin-5-yl)phenyl]benzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NC=CC=N1 IQSDJWBNMBDLOL-UHFFFAOYSA-N 0.000 claims 1
- FCUGJUKRPROMRY-UHFFFAOYSA-N 2,6-difluoro-n-[4-(5-methyl-1,2,3,6-tetrahydropyridin-4-yl)phenyl]benzamide Chemical compound C1CNCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F FCUGJUKRPROMRY-UHFFFAOYSA-N 0.000 claims 1
- DCJOXMRZUKKAOO-UHFFFAOYSA-N 2,6-difluoro-n-[4-[1-(2-methoxyphenyl)-2-methylprop-1-enyl]phenyl]benzamide Chemical compound COC1=CC=CC=C1C(=C(C)C)C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F DCJOXMRZUKKAOO-UHFFFAOYSA-N 0.000 claims 1
- GCXIQYBFNAURFP-UHFFFAOYSA-N 2,6-difluoro-n-[4-[1-(3-methoxyphenyl)-2-methylprop-1-enyl]phenyl]benzamide Chemical compound COC1=CC=CC(C(=C(C)C)C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1 GCXIQYBFNAURFP-UHFFFAOYSA-N 0.000 claims 1
- XWMVWCGAMMPIKF-UHFFFAOYSA-N 2,6-difluoro-n-[4-[1-(4-methoxyphenyl)-2-methylprop-1-enyl]phenyl]benzamide Chemical compound C1=CC(OC)=CC=C1C(=C(C)C)C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F XWMVWCGAMMPIKF-UHFFFAOYSA-N 0.000 claims 1
- BCAVVFXLQGBVTM-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-(1,3-oxazol-5-yl)cyclohepten-1-yl]phenyl]benzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2CCCCCC=2C=2OC=NC=2)C=C1 BCAVVFXLQGBVTM-UHFFFAOYSA-N 0.000 claims 1
- ILNAEDUKNAAFAS-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-(1,3-oxazol-5-yl)cyclohexen-1-yl]phenyl]benzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2CCCCC=2C=2OC=NC=2)C=C1 ILNAEDUKNAAFAS-UHFFFAOYSA-N 0.000 claims 1
- FEFXYVMHIAVMSM-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-(1,3-oxazol-5-yl)cyclopenten-1-yl]phenyl]benzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2CCCC=2C=2OC=NC=2)C=C1 FEFXYVMHIAVMSM-UHFFFAOYSA-N 0.000 claims 1
- AYEAKPSSARDRRD-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-(hydroxymethyl)cyclohepten-1-yl]phenyl]benzamide Chemical compound C1CCCCC(CO)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F AYEAKPSSARDRRD-UHFFFAOYSA-N 0.000 claims 1
- XYUCDYGPJJSDHS-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-(hydroxymethyl)cyclohexen-1-yl]phenyl]benzamide Chemical compound C1CCCC(CO)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F XYUCDYGPJJSDHS-UHFFFAOYSA-N 0.000 claims 1
- SIDRMAFBYIMMQE-UHFFFAOYSA-N 2,6-difluoro-n-[4-[2-(hydroxymethyl)cyclopenten-1-yl]phenyl]benzamide Chemical compound C1CCC(CO)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F SIDRMAFBYIMMQE-UHFFFAOYSA-N 0.000 claims 1
- OPXNIJUNTMAHGQ-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-formyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2CN(CCC=2C=O)C=2SC=CN=2)C=C1 OPXNIJUNTMAHGQ-UHFFFAOYSA-N 0.000 claims 1
- PYJXEYPSJIICDC-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(1-methyltetrazol-5-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NN=NN1C PYJXEYPSJIICDC-UHFFFAOYSA-N 0.000 claims 1
- BCCCDCGGLAACJU-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(2-methyltetrazol-5-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C=1N=NN(C)N=1 BCCCDCGGLAACJU-UHFFFAOYSA-N 0.000 claims 1
- FGQWROFZDNQBQR-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(2h-tetrazol-5-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NN=NN1 FGQWROFZDNQBQR-UHFFFAOYSA-N 0.000 claims 1
- XFZBUOXFDFLOFN-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-(4-methyl-1,3-oxazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound CC1=COC(N2CC(=C(C)CC2)C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=N1 XFZBUOXFDFLOFN-UHFFFAOYSA-N 0.000 claims 1
- UFGAQYIQKKZPBB-UHFFFAOYSA-N 2,6-difluoro-n-[4-[4-methyl-1-[1-(pyridine-3-carbonyl)cyclopropanecarbonyl]-3,6-dihydro-2h-pyridin-5-yl]phenyl]benzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C(=O)C1(C(=O)C=2C=NC=CC=2)CC1 UFGAQYIQKKZPBB-UHFFFAOYSA-N 0.000 claims 1
- WCUYMUUHBDNDNR-UHFFFAOYSA-N 2,6-difluoro-n-[4-[5-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-4-yl]phenyl]benzamide Chemical compound C1C(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CCN1C1=NC=CS1 WCUYMUUHBDNDNR-UHFFFAOYSA-N 0.000 claims 1
- RYGSHTKQDOFFJY-UHFFFAOYSA-N 2,6-difluoro-n-[5-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]pyridin-2-yl]benzamide Chemical compound C1CC(C)=C(C=2C=NC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C1=NC=CS1 RYGSHTKQDOFFJY-UHFFFAOYSA-N 0.000 claims 1
- SZOAENAZGYLCMV-UHFFFAOYSA-N 3-fluoro-n-[4-(2-methylcyclohexen-1-yl)phenyl]pyridine-4-carboxamide Chemical compound C1CCCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F SZOAENAZGYLCMV-UHFFFAOYSA-N 0.000 claims 1
- WMMXBXCBCSCCSM-UHFFFAOYSA-N 3-fluoro-n-[4-(3-methylbut-2-en-2-yl)phenyl]pyridine-4-carboxamide Chemical compound C1=CC(C(C)=C(C)C)=CC=C1NC(=O)C1=CC=NC=C1F WMMXBXCBCSCCSM-UHFFFAOYSA-N 0.000 claims 1
- XZKPCEQWUYPFBH-UHFFFAOYSA-N 3-fluoro-n-[4-(4-methyl-1-pyridin-2-yl-3,6-dihydro-2h-pyridin-5-yl)phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C1=CC=CC=N1 XZKPCEQWUYPFBH-UHFFFAOYSA-N 0.000 claims 1
- XMLPJOCFLNCNEA-UHFFFAOYSA-N 3-fluoro-n-[4-(4-methyl-1-pyrimidin-5-yl-3,6-dihydro-2h-pyridin-5-yl)phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C1=CN=CN=C1 XMLPJOCFLNCNEA-UHFFFAOYSA-N 0.000 claims 1
- IRTFINFJAQMYSR-QGZVFWFLSA-N 3-fluoro-n-[4-[(5r)-2-methyl-5-prop-1-en-2-ylcyclohexen-1-yl]phenyl]pyridine-4-carboxamide Chemical compound C1[C@H](C(=C)C)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F IRTFINFJAQMYSR-QGZVFWFLSA-N 0.000 claims 1
- DASYPMKDRQCGGX-HNNXBMFYSA-N 3-fluoro-n-[4-[(5s)-2-methyl-5-prop-1-en-2-ylcyclohexen-1-yl]pyridin-2-yl]pyridine-4-carboxamide Chemical compound C1[C@@H](C(=C)C)CCC(C)=C1C1=CC=NC(NC(=O)C=2C(=CN=CC=2)F)=C1 DASYPMKDRQCGGX-HNNXBMFYSA-N 0.000 claims 1
- RAYVZRVLHBVZJA-UHFFFAOYSA-N 3-fluoro-n-[4-[2-(1,3-oxazol-5-yl)cyclohexen-1-yl]phenyl]pyridine-4-carboxamide Chemical compound FC1=CN=CC=C1C(=O)NC1=CC=C(C=2CCCCC=2C=2OC=NC=2)C=C1 RAYVZRVLHBVZJA-UHFFFAOYSA-N 0.000 claims 1
- OWUNKIPWLBWUAI-UHFFFAOYSA-N 3-fluoro-n-[4-[4-methyl-1-(1,3-oxazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C1=NC=CO1 OWUNKIPWLBWUAI-UHFFFAOYSA-N 0.000 claims 1
- LHZRDXHNDGFXRP-UHFFFAOYSA-N 3-fluoro-n-[4-[4-methyl-1-(1-methyltetrazol-5-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C1=NN=NN1C LHZRDXHNDGFXRP-UHFFFAOYSA-N 0.000 claims 1
- GTCZZGBKBPGJGH-UHFFFAOYSA-N 3-fluoro-n-[4-[4-methyl-1-(2-methyltetrazol-5-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C=1N=NN(C)N=1 GTCZZGBKBPGJGH-UHFFFAOYSA-N 0.000 claims 1
- KKDPVJPVRYNODQ-UHFFFAOYSA-N 3-fluoro-n-[4-[4-methyl-1-(2h-tetrazol-5-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1C1=NN=NN1 KKDPVJPVRYNODQ-UHFFFAOYSA-N 0.000 claims 1
- AFDKXHAZFATUIU-UHFFFAOYSA-N 3-methyl-n-[4-(2-methyl-1-phenylprop-1-enyl)phenyl]pyridine-4-carboxamide Chemical compound C=1C=C(NC(=O)C=2C(=CN=CC=2)C)C=CC=1C(=C(C)C)C1=CC=CC=C1 AFDKXHAZFATUIU-UHFFFAOYSA-N 0.000 claims 1
- AWSHFQZQWJQKNZ-LJQANCHMSA-N 3-methyl-n-[4-[(5r)-2-methyl-5-prop-1-en-2-ylcyclohexen-1-yl]phenyl]pyridine-4-carboxamide Chemical compound C1[C@H](C(=C)C)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C AWSHFQZQWJQKNZ-LJQANCHMSA-N 0.000 claims 1
- AWSHFQZQWJQKNZ-IBGZPJMESA-N 3-methyl-n-[4-[(5s)-2-methyl-5-prop-1-en-2-ylcyclohexen-1-yl]phenyl]pyridine-4-carboxamide Chemical compound C1[C@@H](C(=C)C)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C AWSHFQZQWJQKNZ-IBGZPJMESA-N 0.000 claims 1
- JQKBHOXSGUGZPJ-UHFFFAOYSA-N 3-methyl-n-[4-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)C)=CC=2)CN1C1=NC=CS1 JQKBHOXSGUGZPJ-UHFFFAOYSA-N 0.000 claims 1
- OOCVOTJHZNTWKH-UHFFFAOYSA-N 4-chloro-n-[4-(2-methylcyclohexen-1-yl)phenyl]-1,3-thiazole-5-carboxamide Chemical compound C1CCCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=C(Cl)N=CS1 OOCVOTJHZNTWKH-UHFFFAOYSA-N 0.000 claims 1
- RUBQGFPSWXWDGF-UHFFFAOYSA-N 4-methyl-n-[4-(2-methylcyclohexen-1-yl)phenyl]pyrimidine-5-carboxamide Chemical compound C1CCCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CN=CN=C1C RUBQGFPSWXWDGF-UHFFFAOYSA-N 0.000 claims 1
- NHHQOYLPBUYHQU-UHFFFAOYSA-N 4-methylthiadiazole-5-carboxylic acid Chemical compound CC=1N=NSC=1C(O)=O NHHQOYLPBUYHQU-UHFFFAOYSA-N 0.000 claims 1
- POOBBEQIUWWXCI-UHFFFAOYSA-N 4-o-ethyl 1-o-methyl 5-[4-[(2,6-difluorobenzoyl)amino]phenyl]-2,3,6,7-tetrahydroazepine-1,4-dicarboxylate Chemical compound C1CN(C(=O)OC)CCC(C(=O)OCC)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F POOBBEQIUWWXCI-UHFFFAOYSA-N 0.000 claims 1
- YOUWHBCVHXEKMR-UHFFFAOYSA-N 5-methyl-n-[4-(2-methylcyclohexen-1-yl)phenyl]pyrimidine-4-carboxamide Chemical compound C1CCCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=NC=NC=C1C YOUWHBCVHXEKMR-UHFFFAOYSA-N 0.000 claims 1
- UGWOIYHQWUMROA-UHFFFAOYSA-N 5-methyl-n-[4-[4-methyl-1-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridin-5-yl]phenyl]pyrimidine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CN=3)C)=CC=2)CN1C1=NC=CS1 UGWOIYHQWUMROA-UHFFFAOYSA-N 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 102000004310 Ion Channels Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- KEXSYBIWPZWVRT-UHFFFAOYSA-N benzyl 4-methyl-5-[4-[(3-methylpyridine-4-carbonyl)amino]phenyl]-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)C)=CC=2)CN1C(=O)OCC1=CC=CC=C1 KEXSYBIWPZWVRT-UHFFFAOYSA-N 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- VHASMDXJHUGLPT-UHFFFAOYSA-N ethyl 1-cyano-4-[4-[(2,6-difluorobenzoyl)amino]phenyl]-3,6-dihydro-2h-pyridine-5-carboxylate Chemical compound C1CN(C#N)CC(C(=O)OCC)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F VHASMDXJHUGLPT-UHFFFAOYSA-N 0.000 claims 1
- VQUGCXGZEYGIIO-UHFFFAOYSA-N ethyl 2-[4-[(2,6-difluorobenzoyl)amino]phenyl]cyclopentene-1-carboxylate Chemical compound C1CCC(C(=O)OCC)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F VQUGCXGZEYGIIO-UHFFFAOYSA-N 0.000 claims 1
- UWFCOUHCFNJMCJ-UHFFFAOYSA-N ethyl 4-[4-[(2,6-difluorobenzoyl)amino]phenyl]-5-methyl-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OCC)CCC(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1C UWFCOUHCFNJMCJ-UHFFFAOYSA-N 0.000 claims 1
- KSKNCNCPMLOGBE-UHFFFAOYSA-N ethyl 5-[4-[(2,6-difluorobenzoyl)amino]phenyl]-4-methyl-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OCC)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F KSKNCNCPMLOGBE-UHFFFAOYSA-N 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- YYJAEZCTXIDVJG-UHFFFAOYSA-N methyl 2-[4-[(2,6-difluorobenzoyl)amino]phenyl]cycloheptene-1-carboxylate Chemical compound C1CCCCC(C(=O)OC)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F YYJAEZCTXIDVJG-UHFFFAOYSA-N 0.000 claims 1
- AIVMLESVOFRGFS-UHFFFAOYSA-N methyl 4-[4-[(2,6-difluorobenzoyl)amino]phenyl]-5-ethenyl-2,3,6,7-tetrahydroazepine-1-carboxylate Chemical compound C1CN(C(=O)OC)CCC(C=C)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F AIVMLESVOFRGFS-UHFFFAOYSA-N 0.000 claims 1
- ZMIBTQHHTWHXLZ-UHFFFAOYSA-N methyl 5-[4-[(2,6-difluorobenzoyl)amino]phenyl]-4-(1,3-thiazol-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C=1C=C(NC(=O)C=2C(=CC=CC=2F)F)C=CC=1C=1CN(C(=O)OC)CCC=1C1=NC=CS1 ZMIBTQHHTWHXLZ-UHFFFAOYSA-N 0.000 claims 1
- DBPMNRCKNAXXSE-UHFFFAOYSA-N methyl 5-[4-[(2,6-difluorobenzoyl)amino]phenyl]-4-methyl-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F DBPMNRCKNAXXSE-UHFFFAOYSA-N 0.000 claims 1
- VADQJARJSNESTB-UHFFFAOYSA-N methyl 5-[4-[(2,6-difluorobenzoyl)amino]phenyl]-4-propan-2-yl-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC)CCC(C(C)C)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F VADQJARJSNESTB-UHFFFAOYSA-N 0.000 claims 1
- CKLJCKJCIMYPJP-UHFFFAOYSA-N methyl 5-[4-[(3-fluoropyridine-4-carbonyl)amino]phenyl]-4-methyl-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F CKLJCKJCIMYPJP-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- DNKWOEHNSGWHDW-UHFFFAOYSA-N n-[4-(1,4-dimethyl-3,6-dihydro-2h-pyridin-5-yl)phenyl]-2,6-difluorobenzamide Chemical compound C1N(C)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F DNKWOEHNSGWHDW-UHFFFAOYSA-N 0.000 claims 1
- MJXVMGDGGBYXOD-UHFFFAOYSA-N n-[4-(1,5-dimethyl-3,6-dihydro-2h-pyridin-4-yl)phenyl]-2,6-difluorobenzamide Chemical compound C1N(C)CCC(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C1C MJXVMGDGGBYXOD-UHFFFAOYSA-N 0.000 claims 1
- MIEXHOAMCYFTQW-UHFFFAOYSA-N n-[4-(1-acetyl-4-methyl-3,6-dihydro-2h-pyridin-5-yl)phenyl]-2,6-difluorobenzamide Chemical compound C1N(C(=O)C)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F MIEXHOAMCYFTQW-UHFFFAOYSA-N 0.000 claims 1
- MXKZWKUTNJYWBC-UHFFFAOYSA-N n-[4-(1-benzyl-4-methyl-3,6-dihydro-2h-pyridin-5-yl)phenyl]-2,6-difluorobenzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1CC1=CC=CC=C1 MXKZWKUTNJYWBC-UHFFFAOYSA-N 0.000 claims 1
- MWFAJFUSCUTTGE-UHFFFAOYSA-N n-[4-(1-benzyl-5-methyl-3,6-dihydro-2h-pyridin-4-yl)phenyl]-2,6-difluorobenzamide Chemical compound C1C(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CCN1CC1=CC=CC=C1 MWFAJFUSCUTTGE-UHFFFAOYSA-N 0.000 claims 1
- OBKWHYIYPDZVKS-UHFFFAOYSA-N n-[4-(1-carbamothioyl-4-methyl-3,6-dihydro-2h-pyridin-5-yl)phenyl]-2,6-difluorobenzamide Chemical compound C1N(C(N)=S)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F OBKWHYIYPDZVKS-UHFFFAOYSA-N 0.000 claims 1
- RCSUHZUBBHOAKH-UHFFFAOYSA-N n-[4-(1-cyano-4-methyl-3,6-dihydro-2h-pyridin-5-yl)phenyl]-2,6-difluorobenzamide Chemical compound C1N(C#N)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F RCSUHZUBBHOAKH-UHFFFAOYSA-N 0.000 claims 1
- ZTTPKUJBBRHYNL-UHFFFAOYSA-N n-[4-(1-cyano-4-methyl-3,6-dihydro-2h-pyridin-5-yl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound C1N(C#N)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C ZTTPKUJBBRHYNL-UHFFFAOYSA-N 0.000 claims 1
- XAIXBIDDPVWKTR-UHFFFAOYSA-N n-[4-(1-ethylsulfonyl-4-methyl-3,6-dihydro-2h-pyridin-5-yl)phenyl]-3-methylpyridine-4-carboxamide Chemical compound C1N(S(=O)(=O)CC)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C XAIXBIDDPVWKTR-UHFFFAOYSA-N 0.000 claims 1
- NGEQWMFOKGJAGP-UHFFFAOYSA-N n-[4-(2-chlorocyclohexen-1-yl)phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2CCCCC=2Cl)C=C1 NGEQWMFOKGJAGP-UHFFFAOYSA-N 0.000 claims 1
- INSCNDWAMKQSLF-UHFFFAOYSA-N n-[4-(2-ethenylcyclopenten-1-yl)phenyl]-2,6-difluorobenzamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CC=C(C=2CCCC=2C=C)C=C1 INSCNDWAMKQSLF-UHFFFAOYSA-N 0.000 claims 1
- GCTBLNQQVONMQU-UHFFFAOYSA-N n-[4-(2-ethylcyclohexen-1-yl)phenyl]-2,6-difluorobenzamide Chemical compound C1CCCC(CC)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F GCTBLNQQVONMQU-UHFFFAOYSA-N 0.000 claims 1
- UPIATXANDTVHIP-GOSISDBHSA-N n-[4-[(5r)-5-acetyl-2-methylcyclohexen-1-yl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound C1[C@H](C(=O)C)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C UPIATXANDTVHIP-GOSISDBHSA-N 0.000 claims 1
- JEZHPWIQCWCKPB-MBSDFSHPSA-N n-[4-[(5s)-5-[(2r)-1,2-dihydroxypropan-2-yl]-2-methylcyclohexen-1-yl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound C1[C@@H]([C@@](C)(O)CO)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1C JEZHPWIQCWCKPB-MBSDFSHPSA-N 0.000 claims 1
- GCFVZUFDCQLUJM-UHFFFAOYSA-N n-[4-[1-(1,3-benzoxazol-2-yl)-4-methyl-3,6-dihydro-2h-pyridin-5-yl]phenyl]-2,6-difluorobenzamide Chemical compound C1N(C=2OC3=CC=CC=C3N=2)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=C(F)C=CC=C1F GCFVZUFDCQLUJM-UHFFFAOYSA-N 0.000 claims 1
- LYLVOUXYSFATKL-UHFFFAOYSA-N n-[4-[1-(1,3-benzoxazol-2-yl)-4-methyl-3,6-dihydro-2h-pyridin-5-yl]phenyl]-3-fluoropyridine-4-carboxamide Chemical compound C1N(C=2OC3=CC=CC=C3N=2)CCC(C)=C1C(C=C1)=CC=C1NC(=O)C1=CC=NC=C1F LYLVOUXYSFATKL-UHFFFAOYSA-N 0.000 claims 1
- VXDSWWDKIGLETA-UHFFFAOYSA-N n-[4-[1-(4,5-dimethyl-1,3-oxazol-2-yl)-4-methyl-3,6-dihydro-2h-pyridin-5-yl]phenyl]-2,6-difluorobenzamide Chemical compound O1C(C)=C(C)N=C1N1CC(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)=C(C)CC1 VXDSWWDKIGLETA-UHFFFAOYSA-N 0.000 claims 1
- WUEXCPCQSRZDNC-UHFFFAOYSA-N n-[4-[1-(4,5-dimethyl-1,3-oxazol-2-yl)-4-methyl-3,6-dihydro-2h-pyridin-5-yl]phenyl]-5-methylpyrimidine-4-carboxamide Chemical compound O1C(C)=C(C)N=C1N1CC(C=2C=CC(NC(=O)C=3C(=CN=CN=3)C)=CC=2)=C(C)CC1 WUEXCPCQSRZDNC-UHFFFAOYSA-N 0.000 claims 1
- XYPPKEZUIPZYBN-UHFFFAOYSA-N n-[4-[1-(benzenesulfonyl)-4-methyl-3,6-dihydro-2h-pyridin-5-yl]phenyl]-3-methylpyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)C)=CC=2)CN1S(=O)(=O)C1=CC=CC=C1 XYPPKEZUIPZYBN-UHFFFAOYSA-N 0.000 claims 1
- WERPLMUXWPHXPO-UHFFFAOYSA-N n-[4-[1-(cyclopropanecarbonyl)-4-methyl-3,6-dihydro-2h-pyridin-5-yl]phenyl]-2,6-difluorobenzamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CN1C(=O)C1CC1 WERPLMUXWPHXPO-UHFFFAOYSA-N 0.000 claims 1
- ANQIRMIQWIOZEF-UHFFFAOYSA-N n-[4-[1-(cyclopropylmethyl)-4-methyl-3,6-dihydro-2h-pyridin-5-yl]phenyl]-3-fluoropyridine-4-carboxamide Chemical compound C1CC(C)=C(C=2C=CC(NC(=O)C=3C(=CN=CC=3)F)=CC=2)CN1CC1CC1 ANQIRMIQWIOZEF-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 1
- IYSOSNSEOMQFAJ-UHFFFAOYSA-N phenyl 4-[4-[(2,6-difluorobenzoyl)amino]phenyl]-5-methyl-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1C(C)=C(C=2C=CC(NC(=O)C=3C(=CC=CC=3F)F)=CC=2)CCN1C(=O)OC1=CC=CC=C1 IYSOSNSEOMQFAJ-UHFFFAOYSA-N 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 0 CC(C)N(Cc1ccc(*)[n]1C1)c2c1cccc2 Chemical compound CC(C)N(Cc1ccc(*)[n]1C1)c2c1cccc2 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76201606P | 2006-01-25 | 2006-01-25 | |
| US76187506P | 2006-01-25 | 2006-01-25 | |
| PCT/US2007/002307 WO2007087443A2 (en) | 2006-01-25 | 2007-01-25 | Vinyl-phenyl derivatives for inflammation and immune-related uses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009524683A JP2009524683A (ja) | 2009-07-02 |
| JP2009524683A5 true JP2009524683A5 (enExample) | 2010-03-18 |
Family
ID=38309877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008552474A Pending JP2009524683A (ja) | 2006-01-25 | 2007-01-25 | 炎症および免疫関連用途のためのビニル−フェニル誘導体 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7816535B2 (enExample) |
| EP (1) | EP1984337B1 (enExample) |
| JP (1) | JP2009524683A (enExample) |
| AU (1) | AU2007208151B2 (enExample) |
| CA (1) | CA2640091A1 (enExample) |
| TW (1) | TW200806292A (enExample) |
| WO (1) | WO2007087443A2 (enExample) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8065161B2 (en) | 2003-11-13 | 2011-11-22 | Hospira, Inc. | System for maintaining drug information and communicating with medication delivery devices |
| US9123077B2 (en) | 2003-10-07 | 2015-09-01 | Hospira, Inc. | Medication management system |
| EP1983980A4 (en) * | 2006-01-25 | 2010-05-05 | Synta Pharmaceuticals Corp | THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY |
| US20070275960A1 (en) * | 2006-01-25 | 2007-11-29 | Synta Pharmaceuticals Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
| JP5430943B2 (ja) * | 2006-01-25 | 2014-03-05 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫関連用途のための置換芳香族化合物 |
| US8623871B2 (en) * | 2006-01-25 | 2014-01-07 | Synta Pharmaceuticals Corp. | Substituted biaryl compounds for inflammation and immune-related uses |
| WO2007109362A2 (en) | 2006-03-20 | 2007-09-27 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| US8779154B2 (en) * | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| JP2010507176A (ja) | 2006-10-16 | 2010-03-04 | ホスピラ・インコーポレイテツド | 複数のデバイス管理システムからの動態情報および構成情報を比較および利用するためのシステムおよび方法 |
| AU2007322116B2 (en) * | 2006-11-13 | 2013-01-10 | Synta Pharmaceuticals Corp. | Cyclohexenyl-aryl compounds for inflammation and immune-related uses |
| WO2008070692A2 (en) | 2006-12-06 | 2008-06-12 | Smithkline Beecham Corporation | Bicyclic compounds and use as antidiabetics |
| CL2008001933A1 (es) | 2007-06-29 | 2009-09-25 | Millennium Pharm Inc | Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros. |
| EP2185514A4 (en) * | 2007-08-01 | 2011-05-18 | Synta Pharmaceuticals Corp | VINYL-ARYL DERIVATIVES FOR INFLAMMATORY AND IMMUNE DISORDERS |
| CA2699157A1 (en) * | 2007-09-10 | 2009-03-19 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2009076454A2 (en) * | 2007-12-12 | 2009-06-18 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8517990B2 (en) | 2007-12-18 | 2013-08-27 | Hospira, Inc. | User interface improvements for medical devices |
| EP2321303B1 (en) * | 2008-08-27 | 2019-11-27 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8524763B2 (en) * | 2008-09-22 | 2013-09-03 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| CA2739321A1 (en) * | 2008-10-01 | 2010-04-08 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US8143269B2 (en) * | 2008-10-03 | 2012-03-27 | Calcimedica, Inc. | Inhibitors of store operated calcium release |
| US8271106B2 (en) | 2009-04-17 | 2012-09-18 | Hospira, Inc. | System and method for configuring a rule set for medical event management and responses |
| EP2429292B1 (en) * | 2009-05-08 | 2019-04-03 | Georgia State University Research Foundation | Compounds and compositions comprising cdk inhibitors and their use in the treatment of cancer |
| EP2477982A4 (en) * | 2009-09-16 | 2013-04-03 | Calcimedica Inc | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| KR20120130104A (ko) * | 2010-02-01 | 2012-11-28 | 닛뽕 케미파 가부시키가이샤 | Ｇｐｒ119 작동약 |
| PT2563776T (pt) | 2010-04-27 | 2016-09-19 | Calcimedica Inc | Compostos que modulam o cálcio intracelular |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CA2797533A1 (en) | 2010-04-27 | 2011-11-10 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CN106905311A (zh) | 2010-08-27 | 2017-06-30 | 钙医学公司 | 调节细胞内钙的化合物 |
| CN103237800B (zh) * | 2010-10-14 | 2015-10-21 | 田边三菱制药株式会社 | 酰胺衍生物及其用途 |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AU2012299169B2 (en) | 2011-08-19 | 2017-08-24 | Icu Medical, Inc. | Systems and methods for a graphical interface including a graphical representation of medical data |
| WO2013059677A1 (en) | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| EP2769357B1 (en) | 2011-10-21 | 2023-08-30 | ICU Medical, Inc. | Medical device update system |
| CA2853485A1 (en) * | 2011-10-28 | 2013-05-02 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
| US10022498B2 (en) | 2011-12-16 | 2018-07-17 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
| EP2830687B1 (en) | 2012-03-30 | 2019-07-24 | ICU Medical, Inc. | Air detection system and method for detecting air in a pump of an infusion system |
| ES2743160T3 (es) | 2012-07-31 | 2020-02-18 | Icu Medical Inc | Sistema de cuidado de pacientes para medicaciones críticas |
| US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CA2904053C (en) | 2013-03-06 | 2023-01-03 | Hospira, Inc. | Medical device communication method |
| AU2014268355B2 (en) | 2013-05-24 | 2018-06-14 | Icu Medical, Inc. | Multi-sensor infusion system for detecting air or an occlusion in the infusion system |
| CA2913918C (en) | 2013-05-29 | 2022-02-15 | Hospira, Inc. | Infusion system and method of use which prevents over-saturation of an analog-to-digital converter |
| US10166328B2 (en) | 2013-05-29 | 2019-01-01 | Icu Medical, Inc. | Infusion system which utilizes one or more sensors and additional information to make an air determination regarding the infusion system |
| WO2015031774A1 (en) | 2013-08-30 | 2015-03-05 | Hospira, Inc. | System and method of monitoring and managing a remote infusion regimen |
| US9662436B2 (en) | 2013-09-20 | 2017-05-30 | Icu Medical, Inc. | Fail-safe drug infusion therapy system |
| US10311972B2 (en) | 2013-11-11 | 2019-06-04 | Icu Medical, Inc. | Medical device system performance index |
| AU2014353130B9 (en) | 2013-11-19 | 2019-09-05 | Icu Medical, Inc. | Infusion pump automation system and method |
| EP3110474B1 (en) | 2014-02-28 | 2019-12-18 | ICU Medical, Inc. | Infusion system and method which utilizes dual wavelength optical air-in-line detection |
| US9764082B2 (en) | 2014-04-30 | 2017-09-19 | Icu Medical, Inc. | Patient care system with conditional alarm forwarding |
| US11344673B2 (en) | 2014-05-29 | 2022-05-31 | Icu Medical, Inc. | Infusion system and pump with configurable closed loop delivery rate catch-up |
| US9724470B2 (en) | 2014-06-16 | 2017-08-08 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
| US9539383B2 (en) | 2014-09-15 | 2017-01-10 | Hospira, Inc. | System and method that matches delayed infusion auto-programs with manually entered infusion programs and analyzes differences therein |
| US11344668B2 (en) | 2014-12-19 | 2022-05-31 | Icu Medical, Inc. | Infusion system with concurrent TPN/insulin infusion |
| PL3778595T3 (pl) | 2015-02-27 | 2022-04-19 | Calcimedica, Inc. | Leczenie zapalenia trzustki |
| US10850024B2 (en) | 2015-03-02 | 2020-12-01 | Icu Medical, Inc. | Infusion system, device, and method having advanced infusion features |
| CN107847548B (zh) | 2015-05-18 | 2022-06-14 | 贝思以色列女会吏医学中心公司 | P物质、肥大细胞脱颗粒抑制剂和周围神经病 |
| WO2016189417A1 (en) | 2015-05-26 | 2016-12-01 | Hospira, Inc. | Infusion pump system and method with multiple drug library editor source capability |
| JP6738575B2 (ja) | 2015-08-07 | 2020-08-12 | カルシメディカ，インク． | 脳卒中および外傷性脳損傷の処置のためのｃｒａｃチャネル阻害剤の使用 |
| WO2017197024A1 (en) | 2016-05-13 | 2017-11-16 | Icu Medical, Inc. | Infusion pump system and method with common line auto flush |
| US11324888B2 (en) | 2016-06-10 | 2022-05-10 | Icu Medical, Inc. | Acoustic flow sensor for continuous medication flow measurements and feedback control of infusion |
| WO2018013842A1 (en) | 2016-07-14 | 2018-01-18 | Icu Medical, Inc. | Multi-communication path selection and security system for a medical device |
| US20180047567A1 (en) * | 2016-08-09 | 2018-02-15 | Samsung Electronics Co., Ltd. | Method of fabricating thin film |
| US10089055B1 (en) | 2017-12-27 | 2018-10-02 | Icu Medical, Inc. | Synchronized display of screen content on networked devices |
| ES2985889T3 (es) | 2018-07-17 | 2024-11-07 | Icu Medical Inc | Actualización de las bibliotecas de fármacos de bombas de infusión y software operacional en un entorno en red |
| US10861592B2 (en) | 2018-07-17 | 2020-12-08 | Icu Medical, Inc. | Reducing infusion pump network congestion by staggering updates |
| NZ793485A (en) | 2018-07-17 | 2023-06-30 | Icu Medical Inc | Systems and methods for facilitating clinical messaging in a network environment |
| US10950339B2 (en) | 2018-07-17 | 2021-03-16 | Icu Medical, Inc. | Converting pump messages in new pump protocol to standardized dataset messages |
| WO2020023231A1 (en) | 2018-07-26 | 2020-01-30 | Icu Medical, Inc. | Drug library management system |
| US10692595B2 (en) | 2018-07-26 | 2020-06-23 | Icu Medical, Inc. | Drug library dynamic version management |
| KR20210062023A (ko) | 2018-09-14 | 2021-05-28 | 리젠 파마슈티컬스 아게 | Crac 억제제 및 코르티코스테로이드를 포함하는 조성물 및 그의 사용 방법 |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020227403A1 (en) | 2019-05-08 | 2020-11-12 | Icu Medical, Inc. | Threshold signature based medical device management |
| US11427558B1 (en) | 2019-07-11 | 2022-08-30 | ESCAPE Bio, Inc. | Indazoles and azaindazoles as LRRK2 inhibitors |
| US11278671B2 (en) | 2019-12-04 | 2022-03-22 | Icu Medical, Inc. | Infusion pump with safety sequence keypad |
| CN115209952B (zh) | 2020-01-13 | 2025-05-30 | 维基分析有限公司 | 经取代的吡唑并嘧啶及其用途 |
| US11590057B2 (en) | 2020-04-03 | 2023-02-28 | Icu Medical, Inc. | Systems, methods, and components for transferring medical fluids |
| CN113717116A (zh) * | 2020-05-25 | 2021-11-30 | 上海医药工业研究院 | 一种环戊烯类化合物、其制备方法及应用 |
| NZ797085A (en) | 2020-07-21 | 2025-08-29 | Icu Medical Inc | Fluid transfer devices and methods of use |
| WO2022051230A1 (en) | 2020-09-05 | 2022-03-10 | Icu Medical, Inc. | Identity-based secure medical device communications |
| US11135360B1 (en) | 2020-12-07 | 2021-10-05 | Icu Medical, Inc. | Concurrent infusion with common line auto flush |
| USD1091564S1 (en) | 2021-10-13 | 2025-09-02 | Icu Medical, Inc. | Display screen or portion thereof with graphical user interface for a medical device |
| AU2022407460A1 (en) | 2021-12-10 | 2024-06-27 | Icu Medical, Inc. | Medical fluid compounding systems with coordinated flow control |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| AU3803593A (en) | 1992-04-02 | 1993-11-08 | Smithkline Beecham Corporation | Compounds |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US6274171B1 (en) | 1996-03-25 | 2001-08-14 | American Home Products Corporation | Extended release formulation of venlafaxine hydrochloride |
| AU751139B2 (en) * | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
| DE10008329A1 (de) | 2000-02-23 | 2001-08-30 | Merck Patent Gmbh | Aminosulfonylbiphenylderivate |
| GB0013378D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
| JO2654B1 (en) * | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
| JO2390B1 (en) | 2001-04-06 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Diphenylcarboxamides act as lipid-lowering agents |
| TWI319387B (en) | 2002-04-05 | 2010-01-11 | Astrazeneca Ab | Benzamide derivatives |
| PT1651232E (pt) * | 2003-07-23 | 2011-02-16 | Synta Pharmaceuticals Corp | Compostos para inflamação e utilizações imunorelacionadas |
| EP1678147B1 (en) | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| US20050165015A1 (en) * | 2004-01-23 | 2005-07-28 | Ncube Mghele V. | Vanilloid receptor ligands and their use in treatments |
| TW200538433A (en) | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
| US20050250789A1 (en) | 2004-04-20 | 2005-11-10 | Burns David M | Hydroxamic acid derivatives as metalloprotease inhibitors |
| TW200626138A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
| MX2007003342A (es) | 2004-09-21 | 2007-06-05 | Synta Pharmaceutical Corp | Compuestos para inflamacion y usos relacionados con trastornos inmunitarios. |
| RU2423351C2 (ru) | 2004-12-16 | 2011-07-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний |
| TWI441819B (zh) | 2005-01-07 | 2014-06-21 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之化合物 |
| TWI444187B (zh) | 2005-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於炎症及免疫相關用途之噻吩化合物 |
| CN101163478B (zh) | 2005-01-25 | 2013-11-27 | 幸讬制药公司 | 用于炎症及免疫相关用途之化合物 |
| FR2884516B1 (fr) | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| EP1983980A4 (en) | 2006-01-25 | 2010-05-05 | Synta Pharmaceuticals Corp | THIAZOL AND THIADIAZOL COMPOUNDS FOR USES IN RELATION TO INFLAMMATION AND IMMUNITY |
| US8623871B2 (en) | 2006-01-25 | 2014-01-07 | Synta Pharmaceuticals Corp. | Substituted biaryl compounds for inflammation and immune-related uses |
| US20070275960A1 (en) | 2006-01-25 | 2007-11-29 | Synta Pharmaceuticals Corp. | Phenyl and pyridyl compounds for inflammation and immune-related uses |
| JP5430943B2 (ja) | 2006-01-25 | 2014-03-05 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫関連用途のための置換芳香族化合物 |
| US20070254926A1 (en) | 2006-01-31 | 2007-11-01 | Jun Jiang | Pyridylphenyl compounds for inflammation and immune-related uses |
| WO2007109362A2 (en) | 2006-03-20 | 2007-09-27 | Synta Pharmaceuticals Corp. | Benzoimidazolyl-parazine compounds for inflammation and immune-related uses |
| AU2007230911A1 (en) | 2006-03-23 | 2007-10-04 | Synta Pharmaceuticals Corp. | Benzimidazolyl-pyridine compounds for inflammation and immune-related uses |
| US20070254825A1 (en) * | 2006-04-28 | 2007-11-01 | Shannon Thomas G | Enhanced self-warming cleaning products |
| TWI330945B (en) * | 2006-07-06 | 2010-09-21 | Sunplus Technology Co Ltd | Delay control circuit |
| US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| AU2007322116B2 (en) | 2006-11-13 | 2013-01-10 | Synta Pharmaceuticals Corp. | Cyclohexenyl-aryl compounds for inflammation and immune-related uses |
| AU2008219115A1 (en) | 2007-02-16 | 2008-08-28 | Synta Pharmaceuticals Corp. | Substituted fused-ring compounds for inflammation and immune-related uses |
| JP5431323B2 (ja) | 2007-08-01 | 2014-03-05 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途のためのピリジン化合物 |
| EP2185514A4 (en) | 2007-08-01 | 2011-05-18 | Synta Pharmaceuticals Corp | VINYL-ARYL DERIVATIVES FOR INFLAMMATORY AND IMMUNE DISORDERS |
| EP2184994B1 (en) | 2007-08-01 | 2013-09-25 | Synta Pharmaceuticals Corp. | Heterocycle-aryl compounds for inflammation and immune-related uses |
| WO2009038775A1 (en) | 2007-09-20 | 2009-03-26 | Synta Pharmaceuticals Corp. | Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses |
| JP2011509261A (ja) | 2008-01-07 | 2011-03-24 | シンタ ファーマシューティカルズ コーポレーション | 炎症および免疫関連用途向けの化合物 |
-
2007
- 2007-01-25 EP EP07762391.6A patent/EP1984337B1/en active Active
- 2007-01-25 US US11/699,002 patent/US7816535B2/en not_active Expired - Fee Related
- 2007-01-25 WO PCT/US2007/002307 patent/WO2007087443A2/en not_active Ceased
- 2007-01-25 AU AU2007208151A patent/AU2007208151B2/en not_active Ceased
- 2007-01-25 CA CA002640091A patent/CA2640091A1/en not_active Abandoned
- 2007-01-25 TW TW096102795A patent/TW200806292A/zh unknown
- 2007-01-25 JP JP2008552474A patent/JP2009524683A/ja active Pending
-
2010
- 2010-09-28 US US12/892,448 patent/US8729069B2/en not_active Expired - Fee Related
-
2014
- 2014-05-09 US US14/273,576 patent/US20140248299A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009524683A5 (enExample) | ||
| JP2009525285A5 (enExample) | ||
| JP5538894B2 (ja) | 炎症及び免疫関連使用のためのシクロヘキセニル−アリール化合物 | |
| AU2006211646B2 (en) | Compounds for inflammation and immune-related uses | |
| AU2007208225B2 (en) | Thiazole and thiadiazole compounds for inflammation and immune-related uses | |
| JP2009524677A5 (enExample) | ||
| AU2006208045B2 (en) | Compounds for inflammation and immune-related uses | |
| JP2009524678A5 (enExample) | ||
| ES2403368T3 (es) | Compuestos de piridilfenilo para la inflamación y usos inmunorrelacionados | |
| JP2014525444A5 (enExample) | ||
| JP2009524670A5 (enExample) | ||
| AU2009300318A1 (en) | Compounds for inflammation and immune-related uses | |
| JP2009528983A5 (enExample) | ||
| JP2009524678A (ja) | 炎症及び免疫関連用途のためのフェニル及びピリジル化合物 | |
| JP2010540462A5 (enExample) | ||
| HRP20191140T1 (hr) | Spojevi i pripravci kao inhibitori c-kit kinaze | |
| JP2007519735A5 (enExample) | ||
| WO2010039237A1 (en) | Compounds for inflammation and immune-related uses | |
| JP2020516671A5 (enExample) | ||
| AU2009300316A1 (en) | Compounds for inflammation and immune-related uses | |
| CN101137624A (zh) | 用于炎症与免疫相关用途的化合物 | |
| AU2013201925A1 (en) | Phenyl and Pyridyl Compounds For Inflammation and Immune-Related Uses |